PFE Stock Price and Quote: Pfizer Inc trades flat as biotech rivals join COVID-19 vaccine race
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NYSE:PFE gains 0.22% as broader markets continue to rally on Tuesday.
- Biotech giant AstraZeneca announces its COVID-19 vaccine candidate as the ‘vaccine for the world’.
- Regeneron also receives emergency use authorization from the FDA.
NYSE:PFE has not performed as one would imagine a stock would after announcing a high efficacy rate for one of the most important vaccines in our lifetime. The stock has traded down since the announcement on November 9th, and despite an initial pop shortly afterwards, shares have lost 5% since. On Tuesday, the stock gained a meager 0.22% to close the trading session at $36.60. Pfizer’s partner BioNTech (NASDAQ:BNTX) has experienced an even lower drop as the German biotech firm has seen its stock fall by 11% since the vaccine was announced.
Just as the news of Pfizer providing its first 6.4 million doses by mid-December was released, several other biotech players entered the COVID-19 vaccine discussion. British giant AstraZeneca (NASDAQ:AZN) reported that it is awaiting the final results of its late-stage clinical trials, and could potentially be able to provide limited quantities of its vaccine candidate by the end of the year. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) also entered the fray as its antibody cocktail, made famous by President Trump, was granted EUA or emergency use authorization by the FDA.
PFE stock quote
We knew that Pfizer would not be the only dog in this fight, but thus far, the New York-based pharmaceutical titan has proven to have the highest efficacy rate in its proposed vaccine. What does this mean for Pfizer’s stock? It should remain steady in the meantime as even world-changing announcements have little effect on its price. With a solid dividend yield of 4.16%, it would not be the worst idea to take a small position in Pfizer, as it could be in for a profitable 2021.
- NYSE:PFE gains 0.22% as broader markets continue to rally on Tuesday.
- Biotech giant AstraZeneca announces its COVID-19 vaccine candidate as the ‘vaccine for the world’.
- Regeneron also receives emergency use authorization from the FDA.
NYSE:PFE has not performed as one would imagine a stock would after announcing a high efficacy rate for one of the most important vaccines in our lifetime. The stock has traded down since the announcement on November 9th, and despite an initial pop shortly afterwards, shares have lost 5% since. On Tuesday, the stock gained a meager 0.22% to close the trading session at $36.60. Pfizer’s partner BioNTech (NASDAQ:BNTX) has experienced an even lower drop as the German biotech firm has seen its stock fall by 11% since the vaccine was announced.
Just as the news of Pfizer providing its first 6.4 million doses by mid-December was released, several other biotech players entered the COVID-19 vaccine discussion. British giant AstraZeneca (NASDAQ:AZN) reported that it is awaiting the final results of its late-stage clinical trials, and could potentially be able to provide limited quantities of its vaccine candidate by the end of the year. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) also entered the fray as its antibody cocktail, made famous by President Trump, was granted EUA or emergency use authorization by the FDA.
PFE stock quote
We knew that Pfizer would not be the only dog in this fight, but thus far, the New York-based pharmaceutical titan has proven to have the highest efficacy rate in its proposed vaccine. What does this mean for Pfizer’s stock? It should remain steady in the meantime as even world-changing announcements have little effect on its price. With a solid dividend yield of 4.16%, it would not be the worst idea to take a small position in Pfizer, as it could be in for a profitable 2021.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.